专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5556840A 2',5'-phosphorothioate oligoadenylates as anitiviral agents 失效
标题翻译： 2'，5'-硫代磷酸酯寡聚腺苷酸作为病毒药物
公开(公告)号：US5556840A
公开(公告)日：1996-09-17
申请号：US348419
申请日：1994-12-02
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： C07H21/02 , A61K31/70 , A61P31/12 , C07H21/00
CPC分类号： C07H21/00 , Y10S514/889
摘要： Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internecleotide phosphorothioate linkages is of the Sp configuration possess increased antiviral activity and/or metabolic stability.
摘要翻译：其中n为1或2，m为0,1,2或3的式（I）的光学活性化合物具有抗病毒活性。下式的化合物其中至少一种核苷酸硫代磷酸酯键是+ E，非S + EE p构型具有增加的抗病毒活性和/或代谢稳定性。

2. 发明授权

US5405939A 2',5'-phosphorothioate oligoadenylates and their covalent conjugates with polylysine 失效
标题翻译： 2'，5'-硫代磷酸寡聚腺苷酸及其与聚赖氨酸的共价缀合物
公开(公告)号：US5405939A
公开(公告)日：1995-04-11
申请号：US915771
申请日：1992-07-16
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： C07H21/02 , A61K31/70 , A61P31/12 , C07H21/00 , C07K9/00
CPC分类号： C07H21/00 , Y10S514/889
摘要： Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internucleotide phosphorothioate linkages is of the Sp configuration possess increased antiviral activity and/or metabolic stability.
摘要翻译：其中n为1或2，m为0,1,2或3的式（Ⅰ）的光学活性化合物具有抗病毒活性。下式的化合物其中至少一个核苷酸硫代磷酸酯键是Sp构型具有增加的抗病毒活性和/或代谢稳定性。

3. 发明授权

US4990498A 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof 失效
标题翻译： 2-和8-叠氮基（2'-5'）寡聚腺苷酸及其抗病毒用途
公开(公告)号：US4990498A
公开(公告)日：1991-02-05
申请号：US186414
申请日：1988-04-26
申请人： Robert J. Suhadolnik
发明人： Robert J. Suhadolnik
IPC分类号： C07H21/00
CPC分类号： C07H21/00
摘要： Compounds of the formula ##STR1##REFERENCE TO GOVERNMENT GRANTThe invention described herein was made, in part, in the course of work supported by National Institutes of Health Grants GM 27210 and CA 29545, and National Science Foundation Grant PCM 84-15002.
摘要翻译：其中m为0,1,2或3的化合物 n为0,1,2或3; 并且每个R 1和R 2各自独立地为R 1和R 2，氢或N 3，条件是至少一个R 1或R 2为N 3; 及其水溶性盐。式的化合物可激活核糖核酸酶L，导致病毒mRNA或rRNA的切割，从而抑制病毒蛋白的合成。他们也有针对植物感染病毒的活动。这些化合物在UV照射后形成能够共价光刻入（或交联）生物分子的硝基自由基中间体。

4. 发明授权

US06362171B1 Aminoaklanoyl-linked conjugates of 2′,5′-oligoadenylate and antiviral uses thereof 有权
标题翻译： 2'，5'-寡聚腺苷酸的氨基酰基酰基连接的缀合物及其抗病毒用途
公开(公告)号：US06362171B1
公开(公告)日：2002-03-26
申请号：US09445559
申请日：1999-12-09
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： A61K31505
CPC分类号： C07H21/00 , A61K47/554
摘要： Antiviral compounds and the water-soluble salts thereof have formula (I), wherein n is from 1 to 8; R1 is selected from the group consisting of (a), wherein m is zero, 1, 2 or 3; and (b), wherein q is from 1 to 20; R2 is independently selected from the group consisting of oxygen and sulfur; R3 is independently selected from the group consisting of hydrogen and hydroxyl; and R4 is selected from the group consisting of hydrogen, hydroxyl and (b); R5 is selected from the group consisting of hydroxyl and (b); R6 is selected from the group consisting of (c), (d) et (e), wherein x is from 1 to 20; provided that one of R1, R4 and R5 is (b) wherein R6 is defined as above; or water soluble salt thereof.
摘要翻译：抗病毒化合物及其水溶性盐具有式（I），其中n为1至8; R1选自（a），其中m为0,1,2或3; 和（b），其中q为1至20; R2独立地选自氧和硫; R3独立地选自氢和羟基; 并且R 4选自氢，羟基和（b）; R5选自羟基和（b）; R 6选自（c），（d）和（e），其中x为1至20; 条件是R 1，R 4和R 5中的一个是（b）其中R 6如上所定义; 或其水溶性盐。

5. 发明授权

US06207366B1 Chronic fatigue syndrome diagnosis 失效
标题翻译：慢性疲劳综合征诊断
公开(公告)号：US06207366B1
公开(公告)日：2001-03-27
申请号：US09548582
申请日：2000-04-13
申请人： Robert J. Suhadolnik
发明人： Robert J. Suhadolnik
IPC分类号： C12Q100
CPC分类号： C12Q1/34 , G01N33/573
摘要： Chronic fatigue syndrome is diagnosed through quantification of low and high molecular weight forms of RNase L in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. A ratio of low to high molecular weight RNase L of more than 0.15 is characteristic of chronic fatigue syndrome.
摘要翻译：通过定量RNA酶L的低分子量和高分子量形式的核糖核酸酶L的细胞例如外周血单核细胞的细胞提取物来诊断慢性疲劳综合征。低分子量RNase L超过0.15的比例是慢性疲劳综合征的特征。

6. 发明授权

US4859768A Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof 失效
标题翻译： 2'，5'-寡腺苷酸的衍生物及其抗病毒用途
公开(公告)号：US4859768A
公开(公告)日：1989-08-22
申请号：US144602
申请日：1988-01-11
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： C07H21/00 , C07H23/00
CPC分类号： A61K31/7115 , A61K31/712 , A61K47/48123 , C07H21/00 , C07H23/00
摘要： Synthetic analogs of 2',5'-oligoadenylate wherein the aglycon, ribosyl moiety and/or terminal nucleoside have been modified are effective antiviral agents for pharmaceutical and agricultural use. They are particularly useful in inhibiting replication of tobacco mosaic virus. Novel synthetic analogs have the following formulae wherein m=0, 1, 2 and 3 and n=0, 1, 2, 3 or 4: ##STR1##The invention described herein was supported by National Institutes of Health Grant GM-26134 and National Science Foundation Grant PCM-8111752.
摘要翻译：其中糖苷配基，核糖基部分和/或末端核苷已经被修饰的2'，5'-寡腺苷酸的合成类似物是用于制药和农业应用的有效抗病毒剂。它们特别可用于抑制烟草花叶病毒的复制。新的合成类似物具有以下分子式，其中m = 0,1,2和3以及n = 0,1,2,3或4：

7. 发明授权

US06214554B1 Chronic fatigue syndrome diagnosis 有权
标题翻译：慢性疲劳综合征诊断
公开(公告)号：US06214554B1
公开(公告)日：2001-04-10
申请号：US09296211
申请日：1999-04-21
申请人： Robert J. Suhadolnik
发明人： Robert J. Suhadolnik
IPC分类号： C12Q168
CPC分类号： C12Q1/34 , G01N33/573 , G01N2333/922
摘要： Chronic fatigue syndrome is diagnosed through detection of an about 30 kDa RNase L molecule under native conditions in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. Proteins are fractionated according to molecular weight under nondenaturing conditions. The fractionated proteins are assayed for the presence of the about 30 kDa protein having 2-5A-dependent RNase L enzyme activity. The severity of the affliction may be determined by testing for the presence of RNase L molecules having approximate molecular weights of 30 and 80 kDa. The presence of the about 30 kDa RNase L, and the absence of the about 80 kDa RNase L molecule, correlates with severe chronic fatigue syndrome. The presence of both RNase L molecules indicates a less severe chronic fatigue syndrome affliction. Under denaturing conditions, and in the presence of protease inhibitors, chronic fatigue syndrome may be diagnosed through the detection of an about 37 kDa 2-5A binding protein.
摘要翻译：通过在天然条件下检测约30kDa的RNA酶L分子来诊断慢性疲劳综合征，在含有RNase L的细胞例如外周血单核细胞的细胞提取物中。蛋白质在非变性条件下根据分子量分级。测定分级蛋白质是否存在具有2-5A依赖性RNA酶L酶活性的约30kDa蛋白质。可以通过测试具有近似分子量为30和80kDa的RNA酶L分子的存在来确定苦难的严重程度。约30kDa核糖核酸酶L的存在和约80kDa核糖核酸酶L分子的不存在与严重的慢性疲劳综合征相关。两种RNase L分子的存在表明不太严重的慢性疲劳综合症患者。在变性条件下，并且在蛋白酶抑制剂存在下，可以通过检测约37kDa 2-5A结合蛋白来诊断慢性疲劳综合征。

8. 发明授权

US5985565A Chronic fatigue syndrome diagnosis 失效
标题翻译：慢性疲劳综合征诊断
公开(公告)号：US5985565A
公开(公告)日：1999-11-16
申请号：US895120
申请日：1997-07-16
申请人： Robert J. Suhadolnik
发明人： Robert J. Suhadolnik
IPC分类号： C12Q1/34 , C12Q1/68 , G01N33/573
CPC分类号： C12Q1/34 , G01N33/573 , G01N2333/922
摘要： Chronic fatigue syndrome is diagnosed through detection of an about 30 kDa RNase L molecule under native conditions in cellular extracts of RNase L-containing cells such as peripheral blood mononuclear cells. Proteins are fractionated according to molecular weight under nondenaturing conditions. The fractionated proteins are assayed for the presence of the about 30 kDa protein having 2-5A-dependent RNase L enzyme activity. The severity of the affliction may be determined by testing for the presence of RNase L molecules having approximate molecular weights of 30 and 80 kDa. The presence of the about 30 kDa RNase L, and the absence of the about 80 kDa RNase L molecule, correlates with severe chronic fatigue syndrome. The presence of both RNase L molecules indicates a less severe chronic fatigue syndrome affliction. Under denaturing conditions, and in the presence of protease inhibitors, chronic fatigue syndrome may be diagnosed through the detection of an about 37 kDa 2-5A binding protein.
摘要翻译：通过在天然条件下检测约30kDa的RNA酶L分子来诊断慢性疲劳综合征，在含有RNase L的细胞例如外周血单核细胞的细胞提取物中。蛋白质在非变性条件下根据分子量分级。测定分级蛋白质是否存在具有2-5A依赖性RNA酶L酶活性的约30kDa蛋白质。可以通过测试具有近似分子量为30和80kDa的RNA酶L分子的存在来确定苦难的严重程度。约30kDa核糖核酸酶L的存在和约80kDa核糖核酸酶L分子的不存在与严重的慢性疲劳综合征相关。两种RNase L分子的存在表明不太严重的慢性疲劳综合症患者。在变性条件下，并且在蛋白酶抑制剂存在下，可以通过检测约37kDa 2-5A结合蛋白来诊断慢性疲劳综合征。

9. 发明授权

US5188897A Encapsulated 2',5'-phosphorothioate oligoadenylates 失效
标题翻译：封闭的2'，5'-磷酸二乙酯
公开(公告)号：US5188897A
公开(公告)日：1993-02-23
申请号：US499109
申请日：1990-03-26
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： C07H21/00
CPC分类号： C07H21/00 , Y10T428/2984
摘要： Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internucleotide phosphorothioate linkages isREFERENCE TO GOVERNMENT GRANTThe invention described herein was made, in part, in the course of work supported by National Institutes of Health grant PO1 CA-29545 and National Science Foundation grant DMB84-15002.
摘要翻译：其中n为1或2，m为0,1,2或3的式（Ⅰ）的光学活性化合物具有抗病毒活性。下式的化合物其中至少一个核苷酸硫代磷酸酯键是Sp构型具有增加的抗病毒活性和/或代谢稳定性。

10. 发明授权

US4924624A 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof 失效
标题翻译： 2''，5'-硫代磷酸酯寡聚腺苷酸和植物抗病毒用途
公开(公告)号：US4924624A
公开(公告)日：1990-05-15
申请号：US112591
申请日：1987-10-22
申请人： Robert J. Suhadolnik , Wolfgang Pfleiderer
发明人： Robert J. Suhadolnik , Wolfgang Pfleiderer
IPC分类号： C07H21/02 , A61K31/70 , A61P31/12 , C07H21/00
CPC分类号： C07H21/00 , Y10S514/889
摘要： Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internucleotide phosphorothioate linkages is of the Sp configuration possess increased antiviral activity and/or metabolic stability.
摘要翻译：其中n为1或2且m为0,1,2或3的式（Ⅰ）的光学活性化合物具有抗病毒活性。下式的化合物其中至少一个核苷酸硫代磷酸酯键是Sp构型具有增加的抗病毒活性和/或代谢稳定性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式